TY -的T1 -协会研究晚发性阿尔茨海默氏症的风险变异和记忆衰退(PD5.006) JF -神经学乔-神经病学SP - PD5.006 LP - PD5.006六世- 80 - 7补充AU -密涅瓦Carrasquillo AU首页 -茱莉亚骗子盟盟奥托佩德拉泽弗农Pankratz说道AU -艾伦Mariet盟Thuy阮盟金伯利Malphrus AU -马李盟吉娜Bisceglio AU -罗伯茨玫瑰花蕾盟约翰卢卡斯AU -罗伯特Ivnik AU -玛丽Machulda AU -尼尔Graff-Radford AU -罗纳德·彼得森AU -史蒂文Younkin盟Nilufer tan Y1 - 2013/02/12 UR - //www.ez-admanager.com/content/80/7_Supplement/PD5.006.abstract N2 -目的:探讨晚发性阿尔茨海默氏症(负载)风险变异识别从全基因组关联研究(GWAS)的一系列纵向对人类记忆的影响下降。背景:最近GWAS负载病例对照系列的确认单核苷酸多态性(snp) 9个位点与疾病风险。调查这些变异影响AD-related表型可能提供有价值的信息关于下游生物遗传变异的结果。设计/方法:我们评估了一系列前瞻性收集的1441个白人受试者从梅奥诊所研究衰老的基因分型结果(MCSA)的前9负荷风险从九负载GWAS snp位点和调查协会与斜坡变化的逻辑内存延迟回忆成绩的韦氏记忆量表——收集纵向。混合效应模型被用来估计个人斜坡(随机)和拦截(固定)。这些都是用于线性回归评估协会基因型与认知的斜坡上,调整了年龄、性别、APOE4剂量,多年的教育,和诊断。结果:APOEε4剂量是一个重要的协变量在所有模型与负面记忆斜率估计,如预期(术中;1.4 e - 3)。CD33 rs3865444 (p = 0.019)和BIN1 rs744373 (p = 0.028)单核苷酸多态性与负面记忆斜率估计有名义上的重大关联。BIN1风险等位基因与更消极的斜坡上,虽然这是CD33的保护性等位基因有更多的负面记忆斜率估计,表明更快的记忆下降。结论:我们的研究结果表明,使用的内存斜坡从纵向收集系列可能是一个有价值的表型在评估风险变异在人类认知负载的作用。这些结果需要确认类似的系列。此外,额外的认知斜坡和组合基因型分数需要评估在这些和其他系列。支持:国家老龄研究所(R01 032990净和R01 AG018023 NRG-R SGY); Mayo Alzheimer's Disease Research Center: (P50 AG016574 to RCP, NRG-R, SGY, and NET); GHR Foundation Award for Alzheimer's Disease Research (MMC).Disclosure: Dr. Carrasquillo has nothing to disclose. Dr. Crook has nothing to disclose. Dr. Pedraza has nothing to disclose. Dr. Pankratz received financial support for research activities from Abbott Laboratories. Dr. Allen has nothing to disclose. Dr. Nguyen has nothing to disclose. Dr. Malphrus has nothing to disclose. Dr. Ma has nothing to disclose. Dr. Bisceglio has nothing to disclose. Dr. Roberts has received research support from Abbott Laboratories. Dr. Lucas has nothing to disclose. Dr. Ivnik has nothing to disclose. Dr. Machulda has nothing to disclose. Dr. Graff-Radford has received personal compensation for activities with Codman. Dr. Graff-Radford has received personal compensation in an editorial capacity for the Neurologist. Dr. Graff-Radford has received research support from Janssen, Pfizer Pharmaceuticals, Medivation, Forrest, and Allon. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., Janssen Alzheimer's Immunotherapy, Elan Pharmaceuticals, GE Healthcare, and Novartis. Dr. Younkin has nothing to disclose. Dr. Taner has nothing to disclose.Wednesday, March 20 2013, 2:00 pm-7:00 pm ER -